Aventiv Research

1. Allergan Inc. $2,031,646 177 payments
2. AbbVie, Inc. $236,125 60 payments
3. Novartis Pharmaceuticals Corporation $139,222 9 payments
4. Bayer HealthCare Pharmaceuticals Inc. $136,394 47 payments
5. Merck Sharp & Dohme Corporation $131,908 7 payments
6. Seqirus USA Inc $118,402 200 payments
7. Boehringer Ingelheim Pharma GmbH & Co.KG $103,691 4 payments
8. Boehringer Ingelheim International GmbH $87,310 9 payments
9. AstraZeneca Pharmaceuticals LP $58,481 7 payments
10. Sanofi Pasteur Inc. $55,258 6 payments

1. Ph 3 Open-label Extension Study $453,478 13 payments
2. Ph 3 Open-label Extension Study $324,612 14 payments
3. Ph 3 Pivotal LCL and GL+ LCL - US/EU $241,118 16 payments
4. Ph 3 Pivotal LCL and GL LCL - USEU $218,840 6 payments
5. Empa-Kidney $191,001 13 payments
6. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Treatment of Migraine When Adminstered During the Premonitory Phase $180,373 13 payments
7. Ph 3 Pivotal GL Only - USEU $158,830 7 payments
8. Ph 3 Pivotal GL Only - US/EU $158,390 15 payments
9. A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-na Adults 18 to 64 years of Age With Increased Risk for Pneumococcal Disease $96,238 4 payments
10. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $91,503 12 payments

1. Patient care $37,801 22 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.